Breaking News Headlines Today | Ground News

See every side of every news story

targetedonc.com image

News from targetedonc.com

Ground News rates targetedonc.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about targetedonc.com

Where is targetedonc.com located?targetedonc.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top targetedonc.com News

FDA Grants Priority Review to AZ's Datroway for Metastatic Triple Negative Breast Cancer

FDA · United States

FDA Grants Priority Review to AZ's Datroway for Metastatic Triple Negative Breast Cancer

60% Center coverage: 5 sources

FDA has granted priority review to AstraZeneca's Datroway for the first-line treatment of metastatic TNBC treatment.See the Story

TuHURA Biosciences Received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

United States · United States

TuHURA Biosciences Received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

TuHURA Biosciences, Inc. announced that the US FDA Office of Orphan Products Development has granted Orphan Drug Designation to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma. [TuHURA Biosciences, Inc.] Press Release See the Story

CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

New data reveals CD47 expression as a key biomarker for predicting evorpacept's effectiveness in treating HER2-positive metastatic breast cancer.See the Story

Breaking News Topics Related to targetedonc.com